Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
With a new CEO prepared to take the reins next month and three key launches on deck for 2026 and 2027, Takeda is ready to shake off the generic-related declines that have plagued revenues in recent | Takeda's multiyear slim-down is expected to hit about 4,500 roles during the 2026 fiscal year, resulting in about 170 billion Japanese yen ($1.07 billion) in restructuring costs and some 100 billion yen ($633 million) in gross savings for 2026.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise

Takeda to target 4,500 jobs as incoming CEO continues restructuring

Pharmaceutical Takeda to cut 4,500 from global workforce

Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers

Weiterer Schlag für die Schweizer Pharmaindustrie: Takeda streicht bis zu 280 Stellen

Daiichi Sankyo posts 'extraordinary loss' of nearly $1B after overestimating need for ADC capacity

Here's what the CEOs at major for-profit payers earned last year

Takeda will cut roughly 9% of its workforce over the next fiscal year as the next CEO puts her stamp on a yearslong restructuring.

Bristol Myers Squibb and Hengrui Pharma signed a massive deal worth up to $15.2 billion. Takeda aims to cut 4,500 jobs in fiscal…

Japanese pharmaceutical Takeda has announced layoffs affecting 4,500 people from its global workforce, which may impact employees…

Hundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its…

Vor zwei Jahren wurden in der Europazentrale des japanischen Unternehmens Takeda bereits 120 Arbeitsplätze abgebaut. Nun trifft…

Strengthening core CDO values for cell line development | Strengthening core CDO values for cell line development